oru.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
BETA
Publikationer (10 of 41) Visa alla publikationer
Adolfsson, E., Helenius, G., Friberg, Ö., Samano, N., Fröbert, O. & Johansson, K. (2020). Bone marrow- and adipose tissue-derived mesenchymal stem cells from donors with coronary artery disease: growth, yield, gene expression and the effect of oxygen concentration. Scandinavian Journal of Clinical and Laboratory Investigation, 1-9
Öppna denna publikation i ny flik eller fönster >>Bone marrow- and adipose tissue-derived mesenchymal stem cells from donors with coronary artery disease: growth, yield, gene expression and the effect of oxygen concentration
Visa övriga...
2020 (Engelska)Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, E-ISSN 1502-7686, s. 1-9Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

Mesenchymal stem cells (MSCs) for cardiovascular cell therapy are procured from different sources including bone marrow and adipose tissue. Differently located MSCs differ in growth potential, differentiation ability and gene expression when cultured in vitro, and studies show different healing abilities for different MSC subgroups. In this study, bone marrow derived MSCs (BMSCs) and adipose tissue derived MSCs (ADSCs) from six human donors with coronary artery disease were compared for growth potential and expression of target genes (Angpt1, LIF, HGF, TGF-β1 and VEGF-A) in response to exposure to 1% and 5% O2, for up to 48 h. We found greater growth of ADSCs compared to BMSCs. ADSCs expressed higher levels of Angpt1, LIF and TGF-β1 and equal levels of VEGF-A and HGF as BMSCs. In BMSCs, exposure to low oxygen resulted in upregulation of TGF-β1, whereas other target genes were unaffected. Upregulation was only present at 1% O2. In ADSCs, LIF was upregulated in both oxygen concentrations, whereas Angpt1 was upregulated only at 1% O2. Different response to reduced oxygen culture conditions is of relevance when expanding cells in vitro prior to administration. These findings indicate ADSCs as better suited for cardiovascular cell therapy compared to BMSCs.

Ort, förlag, år, upplaga, sidor
Taylor & Francis, 2020
Nyckelord
Adipose tissue, bone marrow, cardiovascular diseases, cell- and tissue-based therapy, heart failure, humans, hypoxia, mesenchymal stem cells
Nationell ämneskategori
Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:oru:diva-80807 (URN)10.1080/00365513.2020.1741023 (DOI)000524023000001 ()32189529 (PubMedID)
Tillgänglig från: 2020-03-23 Skapad: 2020-03-23 Senast uppdaterad: 2020-04-20Bibliografiskt granskad
Kaliff, M., Karlsson, M., Sorbe, B., Bohr Mordhorst, L., Helenius, G. & Lillsunde-Larsson, G. (2020). HPV-negative Tumors in a Swedish Cohort of Cervical Cancer. International Journal of Gynecological Pathology, 39(3), 279-288
Öppna denna publikation i ny flik eller fönster >>HPV-negative Tumors in a Swedish Cohort of Cervical Cancer
Visa övriga...
2020 (Engelska)Ingår i: International Journal of Gynecological Pathology, ISSN 0277-1691, E-ISSN 1538-7151, Vol. 39, nr 3, s. 279-288Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about the group of CCs that test HPV negative. The aim of this study was to reinvestigate a proportion of cervical tumors with a primary negative or invalid test result. Reinvestigation with repeated genotyping (targeting L1) was followed by analysis with an alternative target method (targeting E6/E7) on existing or additional tumor material. Consistently negative tumors were histologically evaluated, and cases with low or lacking tumor cell content, consistent invalid test results, or with suspicion of other than cervical origin were excluded. HPV-negative cases were thereafter subjected to immunohistochemistry (Cytokeratin 5, pan cytokeratin, protein 63, P16, and P53). The HPV-negative proportion could after reinvestigation be reduced by one-half (14%-7%). Additional positive samples were often detected in late polymerase chain reaction cycles, with an alternative (E6/E7) or the same (L1) target, or with a method using shorter amplicon lengths. Confirmed HPV negativity was significantly associated with worse prognosis, high patient age, longer storage time, and adenocarcinoma histology. Some of the HPV-negative cases showed strong/diffuse p16 immunoreactivity, indicating some remaining false-negative cases. False HPV negativity in this cohort was mainly linked to methodological limitations in the analysis of stored CC material. The small proportion of presumably true HPV-negative adenocarcinomas is not a reason for hesitation in revision to CC screening with primary HPV testing.

Ort, förlag, år, upplaga, sidor
Wolters Kluwer, 2020
Nyckelord
Uterine cervical neoplasms, Papillomaviridae, Human papillomavirus DNA tests, Formalin-fixed paraffin-embedded tissues, False-negative reactions
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-79634 (URN)10.1097/PGP.0000000000000612 (DOI)000526400700012 ()31206367 (PubMedID)
Anmärkning

Supported by Örebro country council research committee in Sweden.

Tillgänglig från: 2020-01-31 Skapad: 2020-01-31 Senast uppdaterad: 2020-04-30Bibliografiskt granskad
Bergengren, L., Karlsson, M. & Helenius, G. (2020). Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program. Cancer Causes and Control, 31(4), 377-381
Öppna denna publikation i ny flik eller fönster >>Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program
2020 (Engelska)Ingår i: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 31, nr 4, s. 377-381Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

PURPOSE: Örebro County introduced an updated screening program 2016 with primary HPV test for women over 30 years and prolonged screening, increasing the cut-off age from 56-60 to 64-70. The aim of this study was to investigate the prevalence of HPV genotypes and their correlation to histological changes in women, 10 years after exclusion from the screening program, due to an eventual implementation of a catch-up program including all women aged 60-70.

METHODS: All women in Örebro County, born 1,946 (n = 1,968), were invited to a liquid-based cell sample with primary HPV screening. Samples were analyzed for hrHPV mRNA and positive samples were genotyped. hrHPV positive women were offered to do a conization.

RESULTS: Out of 809 participants, 31 (3.8%) were hrHPV positive, of these 22 did a conization. Histologically, 5/22 (23%) had LSIL and 5/22 (23%) had HSIL. Normal histology was found in 12/22 (55%). The most prevalent genotypes were HPV 16, 33, 52, 56, and 68. Of the women with HSIL, one case of cervical cancer was confirmed in a recone biopsy after 4 months.

CONCLUSION: The study showed considerable prevalence of hrHPV and histologically confirmed LSIL/HSIL. These data led to catch-up screening for women between 60 and 70 years when overlapping two screening strategies.

Ort, förlag, år, upplaga, sidor
Springer, 2020
Nyckelord
Cervical cancer, HPV genotypes, HPV prevalence, Older women, Screening
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-80175 (URN)10.1007/s10552-020-01278-0 (DOI)000516473600001 ()32076907 (PubMedID)2-s2.0-85079750054 (Scopus ID)
Anmärkning

Funding Agency:

Region Örebro County Research Committee and Örebro University Hospital Research Foundation  OLL-576341 OLL-616292 OLL-639751 OLL-811061

Tillgänglig från: 2020-02-25 Skapad: 2020-02-25 Senast uppdaterad: 2020-04-23Bibliografiskt granskad
Qvick, A., Wirén, A., Rönnqvist, M. & Helenius, G. (2019). Circulating miRNA: a biomarker for classification of lung cancer and benign lung disease. Paper presented at World Congress on Lung Cancer 2019, Barcelona, Spain, September 7-10, 2019. Journal of Thoracic Oncology, 14(10), 311-311, Article ID MA15.07.
Öppna denna publikation i ny flik eller fönster >>Circulating miRNA: a biomarker for classification of lung cancer and benign lung disease
2019 (Engelska)Ingår i: Journal of Thoracic Oncology, ISSN 1556-0864, Vol. 14, nr 10, s. 311-311, artikel-id MA15.07Artikel i tidskrift, Meeting abstract (Övrigt vetenskapligt) Published
Abstract [en]

Background Circulating biomarkers for cancer have great potential for diagnosis as well as follow up of treatment. MicroRNAs (miRNA) are involved in the expression of a majority of proteins with different cell types having different miRNA expression. The aim of this study was to create a circulating miRNA-based model to discriminate patients with lung cancer from patients with benign lung disease. Methods Samples were collected from patients under investigation for lung cancer at Örebro University hospital. Patients were then divided into groups based on diagnosis, which resulted in NSCLC adenocarcinoma (n=24), NSCLC squamous cell carcinoma (n=13), SCLC (n=4) and a heterogeneous group consisting of different benign lung diseases (n=19). Healthy controls were collected separately (n=17). Circulating miRNA was processed using the extraction-free library preparation miRNA Whole Transcriptome Assay with probes for 2083 human mature miRNAs and analyzed with massive parallel sequencing. Differential expression between groups was estimated using edgeR. MiRNAs that had the highest impact on patient grouping were used in a sPLS discriminant analysis. The resulting classification model was validated using the leave-one-out method. Results The final model for comparison between patients with benign lung disease and patients with lung cancer contained 19 miRNAs. The model had an error rate of 15 % with errors distributed evenly between groups. A sub-analysis of patients with mutations in EGFR (n=5) and KRAS (n=6) was performed showing two distinct patterns in miRNA expression. Conclusion MiRNA shows promise as a circulating biomarker for lung cancer but may not be sufficient as an independent classifier. The predictive power may be improved by using several biomarkers in combination. The difference in expression between tumors with different mutations may be derived from alternate driving processes in these tumors.Sequencing results were standardized as counts per million (cpm), miRNA with cpm < 100 was filtered out and quantile normalization and log2 transformation was performed. Differential expression was analyzed using regression model (R software v. 3.5.1, package edgeR v. 3.24.1) with Benjamini-Hochberg correction. The miRNAs that, after correction, had a significant impact on sample groups were kept and analyzed with sparse partial least squares-regression. The resulting model was validated using leave-one-out method.

Ort, förlag, år, upplaga, sidor
Elsevier, 2019
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-77782 (URN)10.1016/j.jtho.2019.08.624 (DOI)000492162201309 ()
Konferens
World Congress on Lung Cancer 2019, Barcelona, Spain, September 7-10, 2019
Tillgänglig från: 2019-11-05 Skapad: 2019-11-05 Senast uppdaterad: 2019-11-12Bibliografiskt granskad
Bergengren, L., Lillsunde-Larsson, G., Helenius, G. & Karlsson, M. G. (2019). HPV-based screening for cervical cancer among women 55-59 years of age. PLoS ONE, 14(6), Article ID e0217108.
Öppna denna publikation i ny flik eller fönster >>HPV-based screening for cervical cancer among women 55-59 years of age
2019 (Engelska)Ingår i: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 14, nr 6, artikel-id e0217108Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

AIM: Many cervical cancers occurs among women over 65 and prevalence of HPV genotypes in this age cohort is sparingly studied. One aim of this study was to study the prevalence and distribution of HPV genotypes in women 55-59 years, with normal cytology when exiting the screening program. Secondly, HPV clearance as well as the value of HPV genotyping and/or liquid based cytology as triage tests for identifying histological dysplasia among women with persistent HPV was studied.

METHODS: Women that exited the screening program with normal cytology, between the years 2012-2014, in Örebro County, Sweden, were invited to this study. A total of 2946 samples were analyzed with a broad-spectrum assay to detect both hrHPV and lrHPV in order to investigate the distribution of genotypes. In the consent group, women with a positive hrHPV test were offered a follow-up test and a cone biopsy for histological confirmation, and a follow up sample 6 months post cone.

RESULTS: The overall prevalence of hrHPV was 7.4% and 59% of them remained hrHPV positive in a follow-up test after 12 months. A total of 99 women had a cone biopsy done, where 19% showed histological dysplasia. HPV 53 was the most common genotype, and among women with histology confirmed LSIL or HSIL, HPV 31 was most common. A positive hrHPV result showed a PPV of 25% for LSIL+ and 12.5%for HSIL+. Using detection of HPV 16/18 genotypes as a triage test for hrHPV positive tests, indicated FNR for histological LSIL+ and HSIL+ of 94% and 87.5% respectively, whilst triage based on cervical cytology had a FNR of 69% for LSIL+ and 37.5% for HSIL+.

CONCLUSION: The most common hrHPV genotypes among women 55-59 years of age were non HPV16/18 genotypes, and in this population, these genotypes represented most of the histological verified HSIL lesions. This result does not support the proposition of a HPV 16/18 triaging test after a positive hrHPV test as a marker of histological HSIL+ cervical lesions in women over 55 years of age. Similarly, cytological triage after a positive hrHPV showed no additional benefit in this population. Specific triaging tests should be validated to follow post-menopausal women with a positive hrHPV test.

Ort, förlag, år, upplaga, sidor
PLOS, 2019
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-74701 (URN)10.1371/journal.pone.0217108 (DOI)000471587000007 ()31199811 (PubMedID)2-s2.0-85067434997 (Scopus ID)
Anmärkning

Funding Agencies:

Region Örebro County Research Committee  

Örebro University Hospital Research Foundation  

BBMRI.se 

Tillgänglig från: 2019-06-17 Skapad: 2019-06-17 Senast uppdaterad: 2020-04-23Bibliografiskt granskad
Östling, H., Kruse, R., Helenius, G. & Lodefalk, M. (2019). Placental expression of microRNAs in infants born small for gestational age. Placenta, 81, 46-53
Öppna denna publikation i ny flik eller fönster >>Placental expression of microRNAs in infants born small for gestational age
2019 (Engelska)Ingår i: Placenta, ISSN 0143-4004, E-ISSN 1532-3102, Vol. 81, s. 46-53Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

INTRODUCTION: The molecular mechanisms behind poor foetal growth are not fully known. The aim of this study was to explore global microRNA expression in placentas of infants born small for gestational age (SGA) compared to infants with a normal birth weight (NBW).

METHODS: Placental biopsies from term infants were identified in a biobank and divided into four groups: infants born SGA with (n = 13) or without (n = 9) exposure to low maternal gestational weight gain (GWG) and infants born with NBWs with (n = 20) or without (n = 26) exposure to low GWG. All women and infants were healthy, and no woman smoked during pregnancy. Only vaginal deliveries were included. Next-generation sequencing was performed with single read sequencing of >9 million reads per sample. Differential microRNA expression was analysed using ANOVA for unequal variances (Welch) with multiple testing corrections through the Benjamini-Hochberg method. A fold change >2 and a corrected p value < 0.05 were considered significant. Adjustments for possible confounding factors were made using a linear regression model.

RESULTS: A total of 1870 known, mature human microRNAs were detected in the sample. MiR-3679-5p and miR-193b-3p were significantly upregulated, and miR-379-3p, miR-335-3p, miR-4532, miR-519e-3p, miR-3065-5p, and miR-105-5p were significantly downregulated after adjustment for potential confounding factors in SGA infants with normal GWG compared to infants with NBWs and normal GWG.

DISCUSSION: Infants born unexplained SGA show differential microRNA expression in their placenta. Important pathways for the differentially expressed microRNAs include inflammation and the insulin-IGF system.

Ort, förlag, år, upplaga, sidor
Elsevier, 2019
Nyckelord
Foetal growth, Inflammation, Placenta, RNA-Sequencing, Small for gestational age, microRNA
Nationell ämneskategori
Reproduktionsmedicin och gynekologi
Identifikatorer
urn:nbn:se:oru:diva-74556 (URN)10.1016/j.placenta.2019.05.001 (DOI)000468874700007 ()31138431 (PubMedID)2-s2.0-85065481896 (Scopus ID)
Anmärkning

Funding Agency:

Research Committee of Region Örebro County and ALF funding Region Örebro County

Tillgänglig från: 2019-06-05 Skapad: 2019-06-05 Senast uppdaterad: 2019-06-14Bibliografiskt granskad
Helenius, G., Lillsunde-Larsson, G., Bergengren, L., Kaliff, M. & Karlsson, M. (2019). Preliminary data from a Swedish self-sampling study in postmenopausal women. In: : . Paper presented at EUROGIN 2019 – International Multidisciplinary HPV Congress, Monte Carlo, Monaco, December 4-7, 2019.
Öppna denna publikation i ny flik eller fönster >>Preliminary data from a Swedish self-sampling study in postmenopausal women
Visa övriga...
2019 (Engelska)Konferensbidrag, Poster (med eller utan abstract) (Övrigt vetenskapligt)
Abstract [en]

Background: An updated screening algorithm was introduced in Sweden 2015. Primary HPV test for women >30 years old and a prolonged screening with the last test after 64 years of age were some of the changes. In the region of Örebro County, the previous cut-off age was 60 years and with a screening interval of 5 years, women left their last sample when they were 55-59 years old. In the shift between two screening programs, a group of women, 60-64 years old, that left the program 5-10 years ago were now included in the new screening. For re-inclusion, a two year long program was formed to catch-up this group of women and screen them according to the new screening algorithm. At the same time a research project investigating self-sampling was launched. At the same time as the women were invited for a last screening sample they were also asked to participate in a study where they should take a vaginal self-test up to one week after their ordinary screening sample was taken by a midwife.

Method: Postmenopausal women between 64-70 years was included in the study. HPV status in samples from midwife sampling (MS) was compared to self-sampling (SS) samples. HPV was analyzed using HPV Aptima and all HPV positive samples, independent of sampling method, was triaged with cytology and followed-up according to national guidelines.

Results: So far, 585 women with paired samples have been included in the study. In the MS, 4% of the women are positive for hrHPV compared to 11% in the SS group. In 486/585 women, the results of the two samples are concordant. Among the non-concordant samples (13%), 62% were positive in SS and negative in MS. The opposite, negative in SS and positive in MS were seen in 4% of the samples. Among the MS negative samples, 32% were invalid in SS. Cytology was used as a triage test for HPV positive women, both for MS and SS. Of 23 hrHPV positive, 18 had normal cytology, 2 ASCUS, 1 LSIL and 1 HSIL. In the samples with abnormal cytology, 4/5 were hrHPV positive in both SS and MS. One sample was positive in SS but negative in MS.

Discussion: In this age group, more women are hrHPV positive in SS compared to MS. This is in line with what other have seen. Among the very few hrHPV positive samples with abnormal cytology, the majority was hrHPV positive in both MS and SS. But since cytology is a poor triage marker in this age group clinical follow-up is needed before the effectiveness of the both sampling methods can be concluded.

Nationell ämneskategori
Medicin och hälsovetenskap Reproduktionsmedicin och gynekologi
Identifikatorer
urn:nbn:se:oru:diva-77781 (URN)
Konferens
EUROGIN 2019 – International Multidisciplinary HPV Congress, Monte Carlo, Monaco, December 4-7, 2019
Tillgänglig från: 2019-11-05 Skapad: 2019-11-05 Senast uppdaterad: 2020-02-03Bibliografiskt granskad
Bergengren, L., Kaliff, M., Lillsunde-Larsson, G., Karlsson, M. & Helenius, G. (2018). Comparison between professional sampling and self-sampling for HPV-based cervical cancer screening among postmenopausal women. International Journal of Gynecology & Obstetrics, 142(3), 359-364
Öppna denna publikation i ny flik eller fönster >>Comparison between professional sampling and self-sampling for HPV-based cervical cancer screening among postmenopausal women
Visa övriga...
2018 (Engelska)Ingår i: International Journal of Gynecology & Obstetrics, ISSN 0020-7292, E-ISSN 1879-3479, Vol. 142, nr 3, s. 359-364Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

OBJECTIVE: To investigate whether self-sampling is as reliable as professional sampling for HPV testing and genotype detection among postmenopausal women.

METHODS: In the present prospective cross-sectional study, women in Örebro County, Sweden, who had high-risk HPV (hrHPV) and normal cytology results in exit screening tests conducted in between January 1, 2012, and December 31, 2014, were invited to follow-up screenings between February 24, 2015 and May 15, 2015, that included professional sampling and self-sampling. HPV genotypes were identified by a DNA-based assay that could detect 35 HPV genotypes. Findings between the different sampling methods were compared.

RESULTS: Of 143 women who participated, 119 returned a self-sample. Completely concordant results were observed in 67 of these samples when both hrHPV and low-risk HPV genotypes were analyzed. Overall, 99 (83.2%) women had the same clinically relevant finding from both sampling methods. Twenty women had discordant hrHPV results (hrHPV detected in 10 self-samples vs 10 professionally collected samples; Cohen κ 0.66, 95% confidence interval 0.53-0.80). There was no significant difference between the two sampling methods for clinically significant infections (P>0.99) or extended genotyping (P=0.827).

CONCLUSION: Postmenopausal women could be offered self-sampling devices to increase screening-program coverage while maintaining test quality.

Ort, förlag, år, upplaga, sidor
Wiley-Blackwell Publishing Inc., 2018
Nyckelord
Cervical cancer, HPV, Postmenopausal women, Professional sampling, Screening, Self-sample
Nationell ämneskategori
Cancer och onkologi Reproduktionsmedicin och gynekologi
Identifikatorer
urn:nbn:se:oru:diva-67134 (URN)10.1002/ijgo.12538 (DOI)000440652000017 ()29856071 (PubMedID)2-s2.0-85051073715 (Scopus ID)
Anmärkning

Funding Agencies:

Region Örebro County Research Committee  

Örebro University Hospital Research Foundation  

BBMRI.se

Tillgänglig från: 2018-06-04 Skapad: 2018-06-04 Senast uppdaterad: 2020-04-23Bibliografiskt granskad
Helenius, G., Ottestig, E., Kaliff, M., Lillsunde-Larsson, G., Karlsson, M. & Bergengren, L. (2018). Distribution of HPV-genotypes in a Swedish screening population. In: : . Paper presented at Eurogin 2018 International multidisciplinary HPV Congress, Lisabon Portugal, December 2-5, 2018.
Öppna denna publikation i ny flik eller fönster >>Distribution of HPV-genotypes in a Swedish screening population
Visa övriga...
2018 (Engelska)Konferensbidrag, Poster (med eller utan abstract) (Refereegranskat)
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-69348 (URN)
Konferens
Eurogin 2018 International multidisciplinary HPV Congress, Lisabon Portugal, December 2-5, 2018
Tillgänglig från: 2018-10-08 Skapad: 2018-10-08 Senast uppdaterad: 2018-10-08Bibliografiskt granskad
Kaliff, M., Sorbe, B., Mordhorst, L. B., Helenius, G., Karlsson, M. G. & Lillsunde-Larsson, G. (2018). Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy. OncoTarget, 9(27), 18786-18796
Öppna denna publikation i ny flik eller fönster >>Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy
Visa övriga...
2018 (Engelska)Ingår i: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 9, nr 27, s. 18786-18796Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Cervical cancer (CC) is one of the most common cancers in women and virtually all cases of CC are a result of a persistent infection of human papillomavirus (HPV). For disease detected in early stages there is curing treatment but when diagnosed late with recurring disease and metastasis there are limited possibilities. Here we evaluate HPV impact on treatment resistance and metastatic disease progression. Prevalence and distribution of HPV genotypes and HPV16 variants in a Swedish CC patient cohort (n=209) was evaluated, as well as HPV influence on patient prognosis. Tumor samples suitable for analysis (n=204) were genotyped using two different real-time PCR methods. HPV16 variant analysis was made using pyrosequencing. Results showed that HPV prevalence in the total series was 93%. Of the HPV-positive samples, 13% contained multiple infections, typically with two high-risk HPV together. Primary cure rate for the complete series was 95%. Recurrence rate of the complete series was 28% and distant recurrences were most frequent (20%). Patients with tumors containing multiple HPV-strains and particularly HPV genotypes belonging to the alpha 7 and 9 species together had a significantly higher rate of distant tumor recurrences and worse cancer-specific survival rate.

Ort, förlag, år, upplaga, sidor
Impact Journals LLC, 2018
Nyckelord
HPV, cervical cancer, recurrences, survival
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:oru:diva-71672 (URN)10.18632/oncotarget.24666 (DOI)29721161 (PubMedID)2-s2.0-85045206587 (Scopus ID)
Tillgänglig från: 2019-01-22 Skapad: 2019-01-22 Senast uppdaterad: 2019-01-24Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0003-2317-5738

Sök vidare i DiVA

Visa alla publikationer